Payment overview · 2025
General Payments
$815.68
46 reported records · 15 companies
Healthcare provider profile · identity verified
Kate Erin Ryan, DO
Allopathic & Osteopathic Physicians|Family Medicine · HICKORY, NC · NPI 1558865022
Verified facts
What the public records show
CMS Open Payments records show Kate Erin Ryan, DO received $815.68 in general payments during 2025 across 46 reported records.
ABBVIE INC. accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $227.05 | 27.8% | 16 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $174.62 | 21.4% | 10 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $54.63 | 6.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.35 | 5.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.28 | 5.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.65 | 5.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.90 | 4.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.62 | 3.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.34 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $26.42 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.68 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.24 | 2.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.03 | 2.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $22.02 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.85 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $815.68 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $174.62 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $152.05 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.00 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.17 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.28 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.65 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.62 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 281 | 92 |
| Lisinopril | Lisinopril | 191 | 62 |
| Metformin Hcl | Metformin Hcl | 178 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 165 | 57 |
| Omeprazole | Omeprazole | 150 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 124 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 22 |
| Alprazolam | Alprazolam | 104 | 22 |
| Ozempic | Semaglutide | 104 | 25 |
| Simvastatin | Simvastatin | 103 | 32 |
| Gabapentin | Gabapentin | 101 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 20 |
| Losartan Potassium | Losartan Potassium | 87 | 28 |
| Furosemide | Furosemide | 81 | 38 |
| Ibuprofen | Ibuprofen | 80 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 26 |
| Glipizide | Glipizide | 62 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 17 |
| Lovastatin | Lovastatin | 58 | 19 |
| Allopurinol | Allopurinol | 55 | 12 |
| Sertraline Hcl | Sertraline Hcl | 55 | 17 |
| Buspirone Hcl | Buspirone Hcl | 53 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 17 |
| Pregabalin | Pregabalin | 49 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Glimepiride | Glimepiride | 45 | 12 |
| Carvedilol | Carvedilol | 44 | 16 |
| Naproxen | Naproxen | 43 | 18 |
| Trazodone Hcl | Trazodone Hcl | 42 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 40 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 11 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Meloxicam | Meloxicam | 33 | 15 |
| Famotidine | Famotidine | 32 | 12 |
| Farxiga | Dapagliflozin Propanediol | 32 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 12 |
| Prednisone | Prednisone | 31 | 18 |
| Atenolol | Atenolol | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Clonazepam | Clonazepam | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $815.68 · 46 records | ABBVIE INC. | CAPLYTA, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Symbravo, UBRELVY, VIVITROL, VRAYLAR, XIFAXAN, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error